Skip to main content
. Author manuscript; available in PMC: 2013 Jun 9.
Published in final edited form as: Lasers Surg Med. 2011 Sep;43(7):663–675. doi: 10.1002/lsm.21102

Table 3.

Hematology and Chemistries (Mean Value ± SD)1

Treatment
Condition
WBC2
(103/ml)
HgB
(g/dl)
PLT
(103/ml)
NEU
(% WBC)
LYM
(% WBC)
MON
(% WBC)
BUN
(mg/dl)
Creatinine
(mg/dl)
Alk Phos
(U/L)
AST
(U/L)
ALT
(U/L)
CPK
(U/L)
Untreated 2.1 ± 0.8 12.1 ± 0.8 1003 ± 84 27.32 ± 4.27 65.68 ± 6.54 1.10 ± 0.44 32 ± 8 0.37 ± 0.08 90 ± 13 115 ± 81 34 ± 19 573 ± 536
HPPH–only 3.4 ± 1.7 10.8 ± 3.7 855 ± 156 27.83 ± 8.50 67.63 ± 8.94 0.90 ± 0.28 30 ± 8 0.27 ± 0.12 81 ± 29 95 ± 19 203 1873
Light–only 4.8 ± 1.2 12.4 ± 0.6 918 ± 88 23.25 ± 5.54 70.82 ± 9.55 1.00 ± 0.43 26 ± 4 0.30 ± 0 98 ± 14 95 ± 42 24 ± 6 323 ± 237
PDT 4.7 ± 1.8 7.9 ± 3.4 345 ± 2255 86.50 ± 7.795 7.10 ± 5.375 4.03 ± 0.065 39 ± 16 0.27 ± 0.12 59 ± 22 1309 ± 4985 296 ± 724 3178 ± 5984
1

Blood collected from tumor-free animals 24 hours after intrathoracic HPPH-PDT to 50 J/cm or the indicated controls; n=3-6 animals except where noted.

2

WBC, White blood cell count; HgB, hemoglobin; PLT, platelet count; NEU, neutrophils; LYM, lymphocytes; MON, monocytes; BUN, blood urea nitrogen; Alk Phos, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPK, creatine phosphokinase

3

Only 1 sample was available for this condition.

4

Two samples were available for these conditions so comparison to untreated is observational (no statistical tests performed).

5

p < 0.05 for comparison to untreated samples.